Development of methods of chemical and toxicological analysis of Rifabutin in objects of biological origin
https://doi.org/10.21626/vestnik/2022-1/07
About the Authors
Svetlana S. KonovalovaRussian Federation
Elena A. Illarionova
Russian Federation
References
1. State Pharmacopoeia of the Russian Federation. XIV edi-tion. Vol. I. Moscow: Federal electronic medical li-brary (in Russ.). URL: https://docs.rucml.ru/feml/pharma/v14/vol1
2. Kostanyan A.E., Safiulina A.M., Tananaev I.G., Myasoe-dov B.F. Multiphase extraction: design of single- and multistage separation using liquid pseudomembranes. Doklady Chemistry. 2005;404(4-6):203-205
3. Krivonos P.S.,. Avdeev G.S. Improving the effectiveness of tuberculosis chemotherapy in modern conditions. Immunopathology, allergology, infectology. 2000;(3):97-99 (in Russ.)
4. Kuznetsova I.G. Experimental study on the distribution of rifabutin in nanoscale tissues. Vestnik Moskovskogo Gosudarstvennogo Oblastnogo Gumanitarnogo Instituta. Seriya: mediko-biologicheskiye nauki. 2014;(2):42-45 (in Russ.)
5. Nechaeva O.B. Monitoring of tuberculosis and HIV-infection in Russian Federation. Medical alphabet. 2017;3(30):24-33 (in Russ.)
6. Blaschke T.F., Skinner M.H. The clinical pharmacokinetics of rifabutin. Clin Infect Dis. 1996; 22(Suppl 1):S15-21
7. Jamis-Dow C.A., Katki A.G., Collins J.M., Klecker R.W. Rifampin and rifabutin and their metabolism by human liver esterases. Xenobiotica. 1997;27(10):1015-1024. DOI: 10.1080/004982597239994
8. Ji B., Truffot-Pernot C., Lacroix C., Raviglione M.C., O'Brien R.J., Olliaro P., Roscigno G., Grosset J. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis. 1993;148(6 Pt 1):1541-1546. DOI: 10.1164/ajrccm/148.6_Pt_1.1541
9. Lau Y.Y., Hanson G.D., Carel B.J. Determination of rifabutin in human plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Appl. 1996;676(1):125-130. DOI: 10.1016/0378-4347(95)00423-8
10. Lewis R.C., Hatfield N.Z., Narang P.K. A sensitive method for quantitation of rifabutin and its desacetyl metabolite in human biological fluids by high-performance liquid chromatography (HPLC). Pharm Res. 1991;8(11):1434-1440. DOI: 10.1023/a:1015865526655
11. Li R.C., Narang P.K., Poggesi I., Strolin-Benedetti M. A model based assessment of redistribution dependent elimination and bioavailability of rifabutin. Biopharm Drug Dispos. 1996;17(3):223-236. DOI: 10.1002/(SICI)1099-081X(199604)17:3<223::AID-BDD954>3.0.CO;2-S
12. Skinner M.H., Hsieh M., Torseth J., Pauloin D., Bhatia G., Harkonen S., Merigan T.C., Blaschke T.F. Pharmacokinetics of rifabutin. Antimicrob Agents Chemother. 1989;33(8):1237-1241. DOI: 10.1128/AAC.33.8.1237
13. Utkin I., Koudriakova T., Thompson T., Cottrell C., Iatsimirskaia E., Barry J., Vouros P., Gerber N. Isolation and identification of major urinary metabolites of rifabutin in rats and humans. Drug Metab Dispos. 1997;25(8):963-969
Review
For citations:
Konovalova S.S., Illarionova E.A. Development of methods of chemical and toxicological analysis of Rifabutin in objects of biological origin. Humans and their health. 2022;25(1):54-61. (In Russ.) https://doi.org/10.21626/vestnik/2022-1/07